Recent Quotes (30 days)

You have no recent quotes
chg | %

Verisante Technology Inc  

(Public, CVE:VRS)   Watch this stock  
Find more results for CVE:THZ
0.155
-0.005 (-3.12%)
Jul 31 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.15 - 0.16
52 week 0.13 - 0.40
Open 0.15
Vol / Avg. 25,900.00/58,617.00
Mkt cap 12.97M
P/E     -
Div/yield     -
EPS -0.06
Shares 83.70M
Beta 0.42
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -2603.10% -631.51%
Operating margin -2595.35% -633.18%
EBITD margin - -496.54%
Return on average assets -78.88% -79.84%
Return on average equity -92.66% -90.79%
Employees 8 -
CDP Score - -

Address

Suite 306, 2309 West 41st Avenue
VANCOUVER, BC V6M 2A3
Canada
+1-604-6050507 (Phone)
+1-604-6050508 (Fax)

Website links

Description

Verisante Technology, Inc. is a medical device company. The Company is engaged in commercializing systems for the early detection of cancer. The Company's product portfolios include Verisante Aura and Verisante Core. Verisante Aura is a non-invasive Raman spectroscopy system designed to aid medical professionals in the detection of skin cancer. The system provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in less than a second; providing immediate results. The Verisante Core series utilizes the platform technology behind the Verisante Aura for the early detection of other cancers including lung, colon and cervical, using an endoscopic attachment.

Officers and directors

Thomas A. Braun President, Chief Executive Officer, Chief Business Development Officer, Director
Anna Trinh Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary
Joseph Biegel Independent Director
Karen Boodram Independent Director
Age: 49
Christopher John Wesley Dennis Independent Director
Jake J. Thiessen Ph.D. Independent Director
Age: 66